uniQure (NASDAQ:QURE) Shares Gap Down – What’s Next?

uniQure N.V. (NASDAQ:QURE) gapped down before the market opened on Thursday . The stock had previously closed at $25.48, but opened at $21.25. uniQure shares last traded at $22.6410, with a volume of 4,031,125 shares.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on QURE. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research note on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, October 8th. Wells Fargo & Company lowered their price target on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. UBS Group set a $95.00 price objective on uniQure in a report on Thursday, September 25th. Finally, Cantor Fitzgerald boosted their price objective on uniQure from $47.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $64.42.

uniQure Trading Down 10.4%

The company has a market cap of $1.42 billion, a P/E ratio of -5.19 and a beta of 0.59. The firm’s 50 day moving average is $45.82 and its two-hundred day moving average is $26.07. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23.

uniQure (NASDAQ:QURE) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. As a group, equities research analysts anticipate that uniQure N.V. will post -3.75 EPS for the current year.

Insider Activity

In other news, Director Jack Kaye sold 38,810 shares of the business’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total value of $1,177,495.40. Following the transaction, the director owned 20,439 shares in the company, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 226,316 shares of the stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the sale, the chief executive officer owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. This trade represents a 25.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 314,560 shares of company stock worth $12,362,568 in the last 90 days. 4.79% of the stock is owned by company insiders.

Institutional Trading of uniQure

Several large investors have recently modified their holdings of QURE. CIBC Private Wealth Group LLC bought a new stake in shares of uniQure in the 3rd quarter valued at $50,000. Financial Engines Advisors L.L.C. acquired a new stake in uniQure in the third quarter worth $278,000. Alyeska Investment Group L.P. bought a new stake in uniQure in the third quarter valued at $2,335,000. Velan Capital Investment Management LP bought a new stake in uniQure in the third quarter valued at $1,868,000. Finally, Sassicaia Capital Advisers LLC acquired a new position in shares of uniQure during the third quarter valued at about $934,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.